超声评估痛风降尿酸治疗随访中三个结局域:一项观察性研究
这项前瞻性研究对痛风患者降尿酸治疗1年内三个超声结局域(尿酸盐沉积、关节炎症和骨侵蚀)进行观察。在治疗前及治疗后3、6、12个月重复评估双侧膝、踝和第一跖趾关节的痛风石、双轨征、聚集物、滑膜炎和骨侵蚀,并比较不同时间组痛风石、双轨征和聚集物的清除有效率。结果显示血清尿酸下降与痛风石缩小不完全平行,双轨征和聚集物清除率在不同时间组有显著差异,骨侵蚀治疗1年未改善。
要点
- 降尿酸治疗1年内血清尿酸下降与痛风石缩小不完全平行。
- 双轨征和聚集物清除率在不同时间组有显著差异,痛风石清除率无显著差异。
- 骨侵蚀在治疗1年后未改善(Z=-1.633,p=0.102)。
核心结论
- 超声对评估痛风降尿酸治疗反应至关重要;血清尿酸下降与痛风石缩小不完全平行,双轨征和聚集物清除率随时间显著变化,骨侵蚀1年未改善。
研究设计与样本
- 前瞻性观察性研究,纳入痛风患者,在降尿酸治疗前及治疗后3、6、12个月重复超声评估双侧膝、踝和第一跖趾关节,计算GLOESS评分并评分骨侵蚀。
关键影像表现/征象
- 评估的超声基本病变包括痛风石、双轨征、聚集物、滑膜炎和骨侵蚀。
- 痛风石、双轨征和聚集物在不同时间组的清除有效率存在差异。
- GLOESS用于观察三个配对关节的炎症,治疗后6个月显著降低(χ2=32.316,p<0.001)。
诊断标准与关键数值
- 痛风石清除率在不同时间组间无显著差异(χ2=1.76,p=0.392)。
- 双轨征清除率在不同时间组间有显著差异(χ2=21.48,p<0.001)。
- 聚集物清除率在不同时间组间有显著差异(χ2=7.75,p=0.018)。
- GLOESS在治疗6个月后显著降低(χ2=32.316,p<0.001)。
- 骨侵蚀评分在治疗1年后未改善(Z=-1.633,p=0.102)。
临床应用与阅片要点
- 超声可用于随访评估痛风降尿酸治疗中尿酸盐沉积、关节炎症和骨侵蚀的变化。
- 血清尿酸下降与痛风石缩小不完全平行,提示需结合超声评估痛风石变化。
- 骨侵蚀在治疗1年内未见改善,随访时应关注骨侵蚀情况。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This prospective study was aimed at observing the changes in three ultrasound (US) outcome domains (urate deposition, joint inflammation and bone erosion) in gout patients within the 1 y on urate-lowering therapy. The elementary lesions, including tophus, double-contour (DC) sign, aggregates, synovitis and bone erosion of the bilateral knee, ankle and first metatarsophalangeal joints, were evaluated repeatedly by US before and after 3, 6 and 12 mo of treatment, and the effective rates of clearance of tophus, DC sign and aggregates in different time groups were compared. A Global OMERACT-EULAR Synovitis Score (GLOESS) was calculated for these three paired joints to observe the inflammation. Bone erosion was also scored. The correlation between serum uric acid levels and tophus size changes was analyzed. Our results indicated that the decrease in serum uric acid levels was not completely parallel to the decrease in tophus size. For tophus, there was no significant difference in the clearance rate between different time groups (χ2 = 1.76, p = 0.392), while for DC sign and aggregates, there were significant differences (χ2 = 21.48, p < 0.001, χ2 = 7.75, p = 0.018). Meanwhile, GLOESS was significantly lower after 6 mo of therapy (χ2 = 32.316, p < 0.001). Additionally, bone erosion had not improved after 1 y of treatment (Z = -1.633, p = 0.102). Thus, US is crucial for assessing response to urate-lowering therapy in gout.
引用
- Zhang W, Zhao D, Wu M, et al. Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study. Ultrasound Med Biol. 2021. PMID: 33785225. doi:10.1016/j.ultrasmedbio.2021.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。